Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2025
ALERT (ChAracterizing uncontroLled sevERe asThma in Canada): Oral corticosteroid and short-acting β2-agonist overuse.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Côté Andréanne, Beach Jeffrey, Reynolds Jenna, Usuba Koyo, Tusin Joshua, Jayakumar Muthu K G, Yu Han Tim Tian, Waserman Susan
Аннотация
BACKGROUND: Approximately 230,000 to 465,000 patients in Canada have severe asthma; of these, 4% to 31% are uncontrolled. Despite increased availability of biologics, many rely on oral corticosteroids (OCSs) or short-acting β2-agonists (SABAs), which are associated with substantial short- and long-term adverse effects.
OBJECTIVE: ALERT aimed to characterize the demographics of patients with severe asthma and uncontrolled severe asthma with and/or without biologics in Canada and describe OCS/SABA and biologic treatment patterns.
METHODS: ALERT was a retrospective descriptive study using longitudinal claims data from IQVIA's private drug plan database and the Ontario drug benefits database. Adult patients with an inferred asthma diagnosis were assessed and selected using a rule-based inference algorithm and further classified as having severe asthma, uncontrolled severe asthma, and uncontrolled severe asthma without biologics, based on eligibility criteria including inhaled therapies and OCS use. Patients were assessed for OCS, SABA, and biologic use in the 12-month analysis period; regional variation was described.
RESULTS: Patients with severe asthma, uncontrolled severe asthma, and uncontrolled severe asthma without biologics had a mean of 2.7, 4.4, and 4.2 OCS claims per patient per year, respectively. Of patients with uncontrolled severe asthma, 8.3% had ≥10 OCS claims. Combined OCS/SABA overuse (≥2 OCS/≥3 SABA claims in the study period) was recorded in 6.1% of patients with severe asthma. Most patients with uncontrolled severe asthma (71.8%) had no biologic claims. Regional disparities in OCS use were observed.
CONCLUSION: Optimization of asthma management through improved diagnosis, patient education, earlier specialist referral, and region-specific improvements is needed to reduce OCS/SABA use and increase biologic uptake for eligible patients.
OBJECTIVE: ALERT aimed to characterize the demographics of patients with severe asthma and uncontrolled severe asthma with and/or without biologics in Canada and describe OCS/SABA and biologic treatment patterns.
METHODS: ALERT was a retrospective descriptive study using longitudinal claims data from IQVIA's private drug plan database and the Ontario drug benefits database. Adult patients with an inferred asthma diagnosis were assessed and selected using a rule-based inference algorithm and further classified as having severe asthma, uncontrolled severe asthma, and uncontrolled severe asthma without biologics, based on eligibility criteria including inhaled therapies and OCS use. Patients were assessed for OCS, SABA, and biologic use in the 12-month analysis period; regional variation was described.
RESULTS: Patients with severe asthma, uncontrolled severe asthma, and uncontrolled severe asthma without biologics had a mean of 2.7, 4.4, and 4.2 OCS claims per patient per year, respectively. Of patients with uncontrolled severe asthma, 8.3% had ≥10 OCS claims. Combined OCS/SABA overuse (≥2 OCS/≥3 SABA claims in the study period) was recorded in 6.1% of patients with severe asthma. Most patients with uncontrolled severe asthma (71.8%) had no biologic claims. Regional disparities in OCS use were observed.
CONCLUSION: Optimization of asthma management through improved diagnosis, patient education, earlier specialist referral, and region-specific improvements is needed to reduce OCS/SABA use and increase biologic uptake for eligible patients.